Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | NMT1 | P30419 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287525 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL13409587 | 0.84 | CYP1A2 (0.56) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL29203362 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL30240829 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL5311868 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL3081290 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL23344659 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL9363504 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL3297100 | 0.79 | CYP1A2 (0.48) | CYP1A2CYP2C9P2RX7SCN10ASCN2A | |
| SCHEMBL164174 | 0.78 | CYP1A2 (0.56) | CYP1A2CYP2C9P2RX7POLBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-2968299-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CYP1A2 760/4885CYP2C9 575/4885P2RX7 4597/4885 |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | P2RX7, P2RX2, P2RX5 | CYP1A2 1272/4885CYP2C9 1237/4885P2RX7 1/4885 |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | P2RX7, P2RX1, P2RX3 | CYP1A2 857/4885CYP2C9 274/4885P2RX7 1/4885 |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CYP1A2 760/4885CYP2C9 575/4885P2RX7 4597/4885 |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CYP1A2 760/4885CYP2C9 575/4885P2RX7 4597/4885 |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CYP1A2 760/4885CYP2C9 575/4885P2RX7 4597/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | CYP1A2 1272/4885CYP2C9 1237/4885P2RX7 1/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | CYP1A2 1202/4885CYP2C9 1090/4885P2RX7 1/4885 |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CYP1A2 760/4885CYP2C9 575/4885P2RX7 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.